Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review

키워드

참고문헌 (83)

1. "GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11" (2013)[URL]
2. van Hagen P, "Preoperative chemoradiotherapy for esophageal or junctional cancer", N Engl J Med, 366, pp.2074~2084 (2012)
3. Wagner AD, "Chemotherapy in advanced gastric cancer : a systematic review and meta-analysis based on aggregate data", J Clin Oncol, 24, pp.2903~2909 (2006)
4. Kang JH, "Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)
5. Seong-Eun Kim, "The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer", Gut and Liver, 3(2), pp.88~94 (2009), 거트앤리버 발행위원회
6. Tian S, "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo", Cancer Sci, 102, pp.1374~1380 (2011)
7. Hicklin DJ, "Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis", J Clin Oncol, 23, pp.1011~1027 (2005)
8. Faivre S, "Molecular basis for sunitinib efficacy and future clinical development", Nat Rev Drug Discov, 6, pp.734~745 (2007)
9. Suri C, "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis", Cell, 87, pp.1171~1180 (1996)
10. Quatrale AE, "New vascular disrupting agents in upper gastrointestinal malignancies", Curr Med Chem, 21, pp.1039~1049 (2014)
11. Zimna A, "Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis : applications and therapies", Biomed Res Int, 2015, pp.549412~ (2015)
12. Moher D, "Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement", BMJ, 339, pp.b2535~ (2009)
13. Shah MA, "Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma", J Clin Oncol, 29, pp.868~874 (2011)
14. Shah MA, "Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma", J Clin Oncol, 24, pp.5201~5206 (2006)
15. Enzinger PC, "Multicenter phase 2: capecitabine (CAP) +oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS)for patients (pts) with metastatic esophagogastric cancer (MEGCA)", J Clin Oncol, 33(Suppl) (2015)
16. El-Rayes BF, "A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers", Ann Oncol, 21, pp.1999~2004 (2010)
17. Uronis HE, "A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas", Oncologist, 18, pp.271~272 (2013)
18. Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
19. Shen L, "Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer : randomized, double-blind, phase III study(AVATAR study)", Gastric Cancer, 18, pp.168~176 (2015)
20. Cunningham D, "Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948)", Eur J Cancer, 51(Suppl 3), pp.S400~ (2015)
21. Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
22. Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
23. Yoon HH, "Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial", J Clin Oncol, 32(Suppl) (2014)
24. Okines AF, "Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine(ECX)in localised gastrooesophageal adenocarcinoma : a safety report", Ann Oncol, 24, pp.702~709 (2013)
25. Enzinger PC, "Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept", placebo for patients (pts)with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA), 2016, pp.34(Suppl 4S), ~
26. Spratlin JL, "Phase I pharmacologic and biologic study of ramucirumab(IMC-1121B), a fully human immunoglobulin G1monoclonal antibody targeting the vascular endothelial growth factor receptor-2", J Clin Oncol, 28, pp.780~787 (2010)
27. Fuchs CS, "REGARD: a phase 3, randomized, doubleblind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and", or fluoropyrimidine-containing combination therapy: age subgroup analysis, 2014, pp.32(Suppl), ~
28. Muro K, "Subgroup analysis of East Asians in RAINBOW : A phase 3trial of ramucirumab plus paclitaxel for advanced gastric cancer", J Gastroenterol Hepatol, 31, pp.581~589 (2016)
29. Muro K, "RAINBOW: a global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL)plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: an age-group analysis", J Clin Oncol, 33(Suppl 3) (2015)
30. Li J, "Apatinib for chemotherapy-refractory advanced metastatic gastric cancer : results from a randomized, placebo-controlled, parallel-arm, phase II trial", J Clin Oncol, 31, pp.3219~3225 (2013)
31. Li J, "Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction", J Clin Oncol, 34, pp.1448~1454 (2016)
32. Koizumi W, "Randomised phase II study of S-1", cisplatin plus TSU-68 vs S-1, Br J Cancer, pp.2013, 109[DOI]
33. Thuss-Patience PC, "Pazopanib and 5-FU", oxaliplatin as first-line treatment in advanced gastric cancer:PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie), 2015, pp.33(Suppl), ~
34. Lee MY, "Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer", J Clin Oncol, 33(Suppl) (2015)
35. Janjigian YY, "Phase II study of FOLFOX plus regorafenib (REGO)in patients with unresectable or metastatic esophagogastric (EG) cancer", J Clin Oncol, 33(Suppl) (2015)
36. Pavlakis N, "Regorafenib for the Treatment of Advanced Gastric Cancer(INTEGRATE) : a multinational placebo-controlled phase II trial", J Clin Oncol, 34, pp.2728~2735 (2016)
37. Sun W, "Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma : ECOG 5203", J Clin Oncol, 28, pp.2947~2951 (2010)
38. Kang Y, "Randomized phase II study of capecitabine and cisplatin with or without sorafenib in patients with metastatic gastric cancer:STARGATE study", Ann Oncol, 25(Suppl 4), pp.iv210~ (2014)
39. Martin-Richard M, "Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study", Invest New Drugs, 31, pp.1573~1579 (2013)
40. Janjigian YY, "Phase II trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer", PLoS One, 10, pp.e0134731~ (2015)
41. Bang YJ, "Phase II study of sunitinib as second-line treatment for advanced gastric cancer", Invest New Drugs, 29, pp.1449~1458 (2011)
42. Yi JH, "Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum", Br J Cancer, 106, pp.1469~1474 (2012)
43. Moehler M, "An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer", Eur J Cancer, 47, pp.1511~1520 (2011)
44. Wu C, "A phase II and pharmacodynamic study of sunitinib in relapsed", refractory oesophageal and gastro-oesophageal cancers, 2015, pp.113, 220~225
45. Alsina M, "Clinical and pharmacodynamic (PD) results of TEL0805 trial: a phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer", J Clin Oncol, 29(Suppl) (2011)
46. Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
47. Qin S, "Phase III study of apatinib in advanced gastric cancer:a randomized, double-blind, placebo-controlled trial", J Clin Oncol, 32(Suppl) (2014)
48. Hu-Lowe DD, "Nonclinical antiangiogenesis and antitumor activities of axitinib(AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3", Clin Cancer Res, 14, pp.7272~7283 (2008)
49. 오도연, "Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer", Cancer Research and Treatment, 47(4), pp.687~696 (2015), 대한암학회[DOI]
50. Pick AM, "Pazopanib for the treatment of metastatic renal cell carcinoma", Clin Ther, 34, pp.511~520 (2012)
51. Pavlakis N, "INTEGRATE: a randomized phase II doubleblind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): a study by the Australasian Gastrointestinal Trials Group (AGITG), first results", J Clin Oncol, 33(Suppl 3) (2015)
52. Wilhelm SM, "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", Mol Cancer Ther, 7, pp.3129~3140 (2008)
53. Kim C, "Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer", Invest New Drugs, 30, pp.306~315 (2012)
54. O'Farrell AM, "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo", Blood, 101, pp.3597~3605 (2003)
55. Morelli MP, "Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases", J Cell Physiol, 208, pp.344~353 (2006)
56. Halmos B, "A Phase I study of the combination of oxaliplatin", docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer, 2013, pp.31, 1244~1250
57. Al-Batran SE, "RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: qualityof-life (QoL) results", J Clin Oncol, 32(Suppl) (2014)
58. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
59. Piccart-Gebhart MJ, "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer", N Engl J Med, 353, pp.1659~1672 (2005)
60. Rohrberg KS, "Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab", Cancer Biol Ther, 11, pp.732~739 (2011)
61. Van Cutsem E, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a biomarker evaluation from the AVAGAST randomized phase III trial", J Clin Oncol, 30, pp.2119~2127 (2012)
62. Bais C, "Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications)", J Clin Oncol, 32(Suppl) (2014)
63. Hacker UT, "Evaluation of angiopoietin-2 as a biomarker in gastric cancer : results from the randomised phase III AVAGAST trial", Br J Cancer, 114, pp.855~862 (2016)
64. Fuchs CS, "Candidate biomarker analyses in gastric or gastroesophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL)", J Clin Oncol, 33(Suppl) (2015)
65. Jayson GC, "Antiangiogenic therapy in oncology : current status and future directions", Lancet, 388, pp.518~529 (2016)
66. Ciliberto D, "A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?", Cancer Biol Ther, 16, pp.1148~1159 (2015)
67. Chan D, "Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC):a systematic review and meta-analysis", J Clin Oncol, 33(Suppl), pp.e15111~ (2015)
68. Hsu C, "Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma : a meta-analysis and meta-regression", Gastric Cancer, 15, pp.265~280 (2012)
69. Al-Refaie WB, "The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base", Cancer, 113, pp.461~469 (2008)
70. Kim J, "Race and ethnicity correlate with survival in patients with gastric adenocarcinoma", Ann Oncol, 21, pp.152~160 (2010)
71. Shah MA, "Gastric cancer : a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease", J Natl Compr Canc Netw, 8, pp.437~447 (2010)
72. Gill S, "Asian ethnicityrelated differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center", J Clin Oncol, 21, pp.2070~2076 (2003)
73. Price TJ, "Management of advanced gastric cancer", Expert Rev Gastroenterol Hepatol, 6, pp.199~208 (2012)
74. Kim R, "Geographic differences in approach to advanced gastric cancer: Is there a standard approach", Crit Rev Oncol Hematol, 88, pp.416~426 (2013)
75. Hironaka S, "Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial", J Clin Oncol, 31, pp.4438~4444 (2013)
76. Shitara K, "Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer : analysis of 36 randomized trials", Invest New Drugs, 30, pp.1224~1231 (2012)
77. Paoletti X, "Progression-free survival as a surrogate for overall survival in advanced", recurrent gastric cancer trials : a meta-analysis, 2013, pp.105, 1667~1670
78. Park SH, "Second-line chemotherapy for patients with oesophagogastric adenocarcinoma", Lancet Oncol, 15, pp.8~10 (2014)
79. Kim SM, "Chemotherapy beyond second-line in advanced gastric cancer", World J Gastroenterol, 21, pp.8811~8816 (2015)
80. Shaked Y, "Rapid chemotherapy-induced acute endothelial progenitor cell mobilization : implications for antiangiogenic drugs as chemosensitizing agents", Cancer Cell, 14, pp.263~273 (2008)
81. Yasuda S, "Simultaneous blockade of programmed death 1and vascular endothelial growth factor receptor 2(VEGFR2)induces synergistic anti-tumour effect in vivo", Clin Exp Immunol, 172, pp.500~506 (2013)
82. Huang Y, "Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy", Proc Natl Acad Sci USA, 109, pp.17561~17566 (2012)
83. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)

관련 논문AI추천